Beruflich Dokumente
Kultur Dokumente
In 1949, Georgeanna Jones, MD, first described luteal phase deficiency (LPD). [1] The
inadequate secretory transformation of the endometrium, resulting from deficient
progesterone production, has been implicated in both infertility and recurrent pregnancy loss.
[2, 3]
LPD has been the subject of much debate among specialists in the field of reproductive
endocrinology since Jones' introduction of this condition into the medical literature. LPD has
been diagnosed in 3-20% of patients who are infertile and in 5-60% of patients experiencing
recurrent pregnancy loss. However, data show that 6-10% of women who are fertile
demonstrate an inadequate luteal phase, which confirms the need for a better understanding
of normal variations in the menstrual cycle and in variations that could be pathologic.
This article addresses healthy menstrual physiology, the proposed pathophysiology of LPD,
current methods available for diagnosis and treatment, and reasons for the controversy
surrounding this subject.
Following ovulation, the mature ovarian follicle forms the corpus luteum, which becomes a
blood-filled structure that allows the precursor cholesterol to be obtained, initiating
steroidogenesis and resulting in progesterone production. Whereas the follicular phase of the
menstrual cycle can vary in length, the secretory phase lasts approximately 14 days,
correlating with the life span of the corpus luteum. Presumably, progesterone prepares the
endometrium for implantation and maintenance of a pregnancy. If pregnancy occurs, the
production of progesterone from the corpus luteum continues for 7 weeks because of the
tonic release of luteinizing hormone (LH) from the pituitary gland. Studies show that after 7
weeks, the placenta takes over this function. If pregnancy does not occur, menses begins with
the demise of the corpus luteum.
Pathophysiology
The following mechanisms can cause an inadequate endometrial response to hormonal
stimulation during the luteal phase. [4]
Abnormal luteinization
An inadequate LH release can cause a decrease in androstenedione from the theca cells. Less
substrate results in a decrease in estradiol and, subsequently, lower progesterone levels.
Additionally, a suboptimal LH surge at ovulation causes deficient progesterone because of
inadequate luteinization of the granulosa cells.
Uterine abnormalities
Hypocholesterolemia
Epidemiology
Frequency
United States
International
Mortality/Morbidity
Race
Sex
Age
Luteal phase deficiency primarily affects women during their reproductive years.
History
The patient may report menstrual cycles of less than 26 days or a luteal phase of less than 11
days by basal body temperatures; however, neither of these circumstances can alone be used
to diagnose luteal phase deficiency.
Physical
Physical findings that might aid in the diagnosis of luteal phase dysfunction are those
associated with abnormal endocrine function.
Causes
See Pathophysiology for a full discussion of the causes.
Differential Diagnoses
Hyperprolactinemia
Polycystic Ovarian Syndrome
Thyroid Disease
Laboratory Studies
See the list below:
Serum progesterone levels have been studied as a means to diagnose luteal phase
deficiency (LPD). Early data showed that peak progesterone production occurred in
the mid-luteal phase. Later studies confirmed that progesterone is released in a
pulsatile fashion, suggesting that a single sample is nondiagnostic. The use of multiple
samples to overcome the pulsatile nature of progesterone is expensive and
inconvenient.
Urinary LH kits provide a useful test to estimate the appropriate timing of an
endometrial biopsy (EB). Following a positive test finding, ovulation occurs within
24-26 hours. The EB should be performed on the 12th day of a 14-day luteal phase.
Studies measuring progestin endometrial protein (PEP) have not been conclusive in
diagnosing LPD. Studies regarding cell adhesion molecules or integrins, growth
factors, and cytokines are all in the experimental phase.
Imaging Studies
Ultrasound documentation of ovulation from follicular growth to collapse of the follicle is
very accurate; however, this procedure is too expensive and time consuming to be realistic in
all patients. [5] Ultrasound measurement of endometrial thickness has not been shown to be
effective in the prediction of luteal phase deficiency.
Procedures
See the list below:
Biopsy
o In 1950, Noyes, Hertig, and Rock established that the diagnosis of luteal phase
deficiency (LPD) is centered on histologic dating of the endometrium.
However, the location and time of the biopsy can greatly influence
endometrial biopsy (EB) findings. Some authors believe that mid-luteal phase
biopsy is the best for accurate diagnosis of LPD.
o Biopsies from the fundus of the uterus yield improved histologic samples
compared to those taken from the lower uterine segment. Specimens taken
approximately 1-2 days prior to menses provide better specimens for
interpretation. For example, women with cycles of 28 days should have an EB
performed on the 26th day.
o Histologically, a luteal phase defect provides a biopsy that lags behind the date
of actual endometrial sampling by 3 days or more. To confirm that such a
result is not a variance within the reference range, the biopsy should be
performed in 2 consecutive cycles; however, the discomfort associated with
the biopsy causes difficulty in convincing the patient to have the procedure
performed twice. Several methods can be used to time the EB just prior to
menses. The basal body temperature (BBT) chart is one such method.
The BBT chart can aid in determining the length of the luteal phase. A
luteal phase of less than 11 days may be associated with LPD.
The BBT chart can also assist in timing the EB by observing the
patient's cycle length and performing the biopsy 2 days prior to the
expected menses.
Although the BBT chart is easy and inexpensive, interpretation can be
difficult and frustrating with a woman who is infertile or has suffered
multiple pregnancy losses.
Medical Care
See the list below:
Medication Summary
The goals of pharmacotherapy in luteal phase deficiency are to restore ovarian function,
reduce morbidity, and prevent complications.
Hormone replacements
Class Summary
Bromocriptine (Parlodel)
Used if hyperprolactinemia is the underlying pathology causing LPD. Tablets can be used
vaginally in patients who cannot tolerate adverse GI effects.
Cabergoline (Dostinex)
Long-acting dopamine receptor agonist with high affinity for D2 receptors. Prolactin
secretion by anterior pituitary predominates under hypothalamic inhibitory control exerted
through dopamine.
Medications used to treat luteal phase dysfunction include dopamine receptor agonists
to treat elevated serum prolactin levels.
Thyroid replacement treats hypothyroidism.
Supplemental progesterone increases the lower levels in the luteal phase observed
with this condition.
Clomiphene citrate enhances follicular development and thus increases luteal-phase
progesterone levels.
Human menopausal gonadotropins enhance follicular development and increase
luteal-phase progesterone levels.
Deterrence/Prevention
No methodology prevents luteal phase defect. Maintain a high level of clinical suspicion that
such a condition exists when seeing a patient with infertility or recurrent pregnancy loss.
Complications
Complications are associated with the endometrial biopsy. Be cautious when performing the
biopsy to avoid perforating the uterus. Advise patients to take a nonsteroidal anti-
inflammatory drug (NSAID) prior to the procedure to alleviate uterine cramping. No
antibiotic prophylaxis is needed.
Prognosis
The lack of double-blinded placebo-controlled studies prevents an accurate prognosis for this
condition. A report by the Practice Committee of the American Society for Reproductive
Medicine concluded that there is no significant evidence that LPD alone can cause infertility.
[7]
Patient Education
Patients should keep an accurate menstrual cycle calendar. Abnormal cycle length may
heighten the physician's suspicion that a luteal phase dysfunction exists.
References